China Medical System Holdings (HK:0867) has released an update.
China Medical System Holdings Limited has announced the approval of Lumeblue®, an innovative diagnostic drug for improving colorectal lesion detection during colonoscopies, by China’s National Medical Products Administration. Lumeblue®, which utilizes patented MMX technology for targeted delivery, has shown significant improvement in lesion detection rates in Phase III trials. The company, which acquired exclusive licensing rights in December 2020, plans to expedite the commercialization of the drug in China, following its successful launch in the European Union.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.
